DK1086082T3 - Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister - Google Patents
Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonisterInfo
- Publication number
- DK1086082T3 DK1086082T3 DK99926152T DK99926152T DK1086082T3 DK 1086082 T3 DK1086082 T3 DK 1086082T3 DK 99926152 T DK99926152 T DK 99926152T DK 99926152 T DK99926152 T DK 99926152T DK 1086082 T3 DK1086082 T3 DK 1086082T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- amine
- penten
- pyridyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9828598A | 1998-06-16 | 1998-06-16 | |
US09/098,133 US6232316B1 (en) | 1998-06-16 | 1998-06-16 | Methods for treatment of CNS disorders |
EP99926152A EP1086082B9 (en) | 1998-06-16 | 1999-06-03 | Arylsubstituted olefinic amines and their use as cholinergic receptors agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1086082T3 true DK1086082T3 (da) | 2004-11-22 |
Family
ID=26794206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99926152T DK1086082T3 (da) | 1998-06-16 | 1999-06-03 | Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1086082B9 (ru) |
JP (4) | JP4240815B2 (ru) |
KR (1) | KR100593433B1 (ru) |
AT (1) | ATE273956T1 (ru) |
AU (1) | AU4230799A (ru) |
BR (1) | BR9911325A (ru) |
CA (3) | CA2677519A1 (ru) |
DE (1) | DE69919537T2 (ru) |
DK (1) | DK1086082T3 (ru) |
ES (1) | ES2228054T3 (ru) |
PT (1) | PT1086082E (ru) |
WO (1) | WO1999065876A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
ES2228054T3 (es) * | 1998-06-16 | 2005-04-01 | Targacept, Inc. | Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos. |
AU5326100A (en) * | 1999-06-07 | 2000-12-28 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
CA2383307A1 (en) * | 1999-08-31 | 2001-03-08 | Jared Miller Wagner | Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
PL374384A1 (en) | 2001-12-14 | 2005-10-17 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
AU2004282201A1 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
JP2010535237A (ja) * | 2007-07-31 | 2010-11-18 | ターガセプト・インコーポレイテッド | (2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンの経皮投与 |
WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
JP5595926B2 (ja) | 2007-12-07 | 2014-09-24 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 5−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
CN101981027B (zh) | 2007-12-07 | 2014-08-06 | Abbvie德国有限责任两合公司 | 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途 |
EP2623504A1 (de) | 2007-12-07 | 2013-08-07 | Abbott GmbH & Co. KG | 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
US9463190B2 (en) | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
US9040568B2 (en) | 2009-05-29 | 2015-05-26 | Abbvie Inc. | Pharmaceutical compositions for the treatment of pain |
WO2011146009A1 (en) * | 2010-05-20 | 2011-11-24 | Targacept Inc. | New process for the preparation of aryl substituted olefinic amines |
WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242935A (en) * | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5597716A (en) * | 1993-11-18 | 1997-01-28 | Mitsubishi Rayon Co., Ltd. | Process for producing D-lactic acid and L-lactamide |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
AU4610896A (en) * | 1995-01-06 | 1996-07-24 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
AU5383196A (en) * | 1995-05-17 | 1996-11-29 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
EP1997806A1 (en) * | 1996-04-23 | 2008-12-03 | Targacept, Inc. | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders |
US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
JP2001512486A (ja) * | 1997-02-21 | 2001-08-21 | アール・ジェイ・レイノルズ・タバコ・カンパニー | アリール置換オレフィン型アミン化合物を含む医薬組成物 |
ES2228054T3 (es) * | 1998-06-16 | 2005-04-01 | Targacept, Inc. | Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos. |
-
1999
- 1999-06-03 ES ES99926152T patent/ES2228054T3/es not_active Expired - Lifetime
- 1999-06-03 WO PCT/US1999/012340 patent/WO1999065876A1/en active IP Right Grant
- 1999-06-03 CA CA002677519A patent/CA2677519A1/en not_active Abandoned
- 1999-06-03 AU AU42307/99A patent/AU4230799A/en not_active Abandoned
- 1999-06-03 AT AT99926152T patent/ATE273956T1/de active
- 1999-06-03 JP JP2000554703A patent/JP4240815B2/ja not_active Expired - Fee Related
- 1999-06-03 BR BR9911325-2A patent/BR9911325A/pt not_active Application Discontinuation
- 1999-06-03 DE DE69919537T patent/DE69919537T2/de not_active Expired - Lifetime
- 1999-06-03 CA CA2709735A patent/CA2709735A1/en not_active Abandoned
- 1999-06-03 CA CA002334923A patent/CA2334923C/en not_active Expired - Fee Related
- 1999-06-03 DK DK99926152T patent/DK1086082T3/da active
- 1999-06-03 PT PT99926152T patent/PT1086082E/pt unknown
- 1999-06-03 EP EP99926152A patent/EP1086082B9/en not_active Expired - Lifetime
- 1999-06-03 KR KR1020007014279A patent/KR100593433B1/ko not_active IP Right Cessation
-
2008
- 2008-05-19 JP JP2008130504A patent/JP4896923B2/ja not_active Expired - Fee Related
- 2008-05-19 JP JP2008130502A patent/JP4972608B2/ja not_active Expired - Fee Related
-
2010
- 2010-06-15 JP JP2010135746A patent/JP2010229149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1086082B9 (en) | 2005-03-02 |
BR9911325A (pt) | 2001-04-03 |
DE69919537T2 (de) | 2005-09-08 |
JP2008260774A (ja) | 2008-10-30 |
KR100593433B1 (ko) | 2006-06-28 |
EP1086082A1 (en) | 2001-03-28 |
JP2010229149A (ja) | 2010-10-14 |
DE69919537D1 (de) | 2004-09-23 |
JP2002518373A (ja) | 2002-06-25 |
CA2677519A1 (en) | 1999-12-23 |
ES2228054T3 (es) | 2005-04-01 |
CA2334923A1 (en) | 1999-12-23 |
WO1999065876A1 (en) | 1999-12-23 |
JP4896923B2 (ja) | 2012-03-14 |
JP4240815B2 (ja) | 2009-03-18 |
CA2709735A1 (en) | 1999-12-23 |
AU4230799A (en) | 2000-01-05 |
ATE273956T1 (de) | 2004-09-15 |
JP4972608B2 (ja) | 2012-07-11 |
JP2008255122A (ja) | 2008-10-23 |
KR20010083052A (ko) | 2001-08-31 |
CA2334923C (en) | 2009-09-29 |
EP1086082B1 (en) | 2004-08-18 |
PT1086082E (pt) | 2005-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1086082T3 (da) | Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister | |
NO20005224L (no) | BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse | |
TR200102029T2 (tr) | 1-Heterosiklil ikameli diarilaminler. | |
ATE487710T1 (de) | Chemokin rezeptor bindende heterozyklische verbindungen | |
DK1311269T3 (da) | Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem | |
BR9810342A (pt) | Novos compostos imidazola substituìdos | |
DK1114031T3 (da) | 4-carboxyamino-2-substituerede 1,2,3,4.tetrahydroquinoliner som CETP-inhibitorer | |
NO20031619L (no) | Substituerte indoler, farmasöytiske blandinger inneholdende slike indoler og deres anvendelse som PPAR-gamma-bindende midler | |
TR200300322T2 (tr) | Kemokin alıcısını bağlayan heterosiklik bileşikler | |
DK1114032T3 (da) | 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer | |
PT935465E (pt) | Compostos novos de imidazole substituido | |
DK0946512T3 (da) | 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer | |
TR200100054T2 (tr) | Paroksetin metansülfonat | |
DK1220831T3 (da) | Biaryletherderivater, der er nyttige som monoamingenoptagelsesinhibitorer | |
DK1114033T3 (da) | 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer | |
DE69917296D1 (de) | Neue substituierte triazolverbindungen | |
UY26451A1 (es) | Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas | |
NO20020314L (no) | 2-arylimino-2,3-dihydrotiazoler og deres anvendelse som ligander for somatostatin-reseptorer | |
TR200103276T2 (tr) | Yeterince yağsız siklosporin kompozisyonları | |
NO20003451D0 (no) | 2,3-substituerte indolforbindelser som cox-2 inhibitorer | |
DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
ATE387448T1 (de) | 4,5-pyrazinoxindole als proteinkinasehemmer | |
TR200001452T2 (tr) | Bifenilamidin türevleri. | |
BR0007922A (pt) | Compostos calcilìticos | |
BR9912307A (pt) | Inibidores fkbp |